Loading
A phase 2 trial of Azeliragon in glioma & glioblastoma, run by Cantex Pharmaceuticals, active and no longer recruiting.
Azeliragon in MGMT Unmethylated Glioblastoma is a phase 2 interventional study registered as NCT05986851 by Cantex Pharmaceuticals, with 30 participants enrolled, started 2023-09-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Azeliragon.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Medpace and the tag pipeline.